



Current and Emerging Treatment Landscape of Lung Cancer II: Radiation Oncology Perspective

Dr. Kristin Higgins

Chief Clinical Officer, City of Hope Atlanta

Professor, Dept of Radiation Oncology

City of Hope National Medical Center

Radiation Oncology in lung cancer

- Curative
 - Early stage unresectable (Stage I-II NSCLC)
 - Locally-advanced unresectable NSCLC
 - Limited-stage SCLC
 - Oligo-categories (oligometastatic and oligoprogressive)
- Palliative principles
 - Improve symptoms, prevention of symptoms (i.e. fractures or obstruction), and/or durable local control
 - Often the most difficult of decisions we make
 - Treat vs not treat; what to treat; dose/fractionation; coordination with systemic therapy
 - Brain mets – few vs multiple
- Integration of radiation with systemic therapies with radiation
 - Timing with palliative RT and novel agents

Radiation Oncology Tools

- **Photons**

- Linear Accelerator – traditional linac; CT-based TrueBeam; MRI-based Unity or ViewRay; PET-based Reflexion
- Intensity-modulated RT (IMRT); Volumetric modulated arc therapy (VMAT); Image-guided RT (IGRT); 3 dimensional conformal (3DCRT); hypofractionated RT (i.e. 6-20 fractions); stereotactic body radiation therapy (SBRT or SABR); radiosurgery (SRS, 1 fraction)
- Special equipment – 6 DoF couches; Hypersight (near diagnostic CT quality images); camera-based body surface imaging (for breath hold delivery)

- **Protons**

- Passive scattering (older systems; most have been upgraded)(similar to 3DCRT)
- Pencil-beam scanning (also called intensity-modulated proton therapy or IMPT)
- Volumetric arc proton therapy (not yet FDA approved)
- FLASH therapy – currently research only

- **Brachytherapy** – not used much in lung cancer setting

Radiosurgery options

**Gamma knife –
Frame-based
Brain and BOS**




**Cyberknife-
Brain and body**



**Linac-based
Frameless
Brain and body**




3DCRT - photons




- Palliative RT
- Quick forward planning
- Commonly 30 Gy / 10 fractions or 20/5

VMAT IMRT - photons






- All OARs contoured
- Inverse planning (AI automated)
- Commonly 60-66 Gy in 30-33 fractions with chemo
- Can be hypofractionated (w/o chemo)
- Applies to adaptive RT equipment

IMPT - Protons




- All OARs contoured
- Forward planned
- Commonly 60-66 Gy in 30-33 fractions with chemo
- Can be hypofractionated (w/o chemo)



Size, location, and OARs



Special Features: On-board imaging and Surface Guidance Examples



Patient case



- 74 yo male with severe COPD with newly-diagnosed RUL squamous cell carcinoma involving R4 node. PDL1 is 20%. Has solitary brain metastasis.
- What do you recommend?

Patient Case


Major decisions to make

- Curative vs Palliative
- Operable vs inoperable
 - Brain
 - Lung
- Systemic therapy
 - Palliative setting - optimal systemic therapy first vs. benefit of doubt for curative therapy
 - Curative setting - sequential chemo vs. concurrent with RT
- Radiation therapy
 - Radiation dose, fractionation, volume, method of delivery

Patient Case

Major decisions to make


- Curative vs Palliative
 - Curative
- Operable vs inoperable
 - Brain – non-operative mgmt. w/ SRS
 - Lung – poor pulmonary function, so non-operative
- Systemic therapy
 - Palliative setting - chemo vs. IO vs. both
 - Curative setting - sequential vs. concurrent
 - IO – when to add
- Radiation therapy
 - Radiation dose, fractionation, volume, method of delivery



Patient Case

Pt received SRS first, 21 Gy x 1

Followed by 60 Gy IMRT concurrent chemoRT (weekly carbo-paclitaxel) followed by durvalumab



Conclusions

- The multidisciplinary aspect of lung cancer makes it a fun job
- Rad Onc has a technology focus, but needs optimal integration with systemic therapy to have most impact
- Each patients needs are unique and while we rely on our basic principles in management, it's ok to think outside of the box and meet our patients needs

Questions?